StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $4.32 | $4.23 | -2.08% | 0.2M |
| 05-14 | $4.20 | $4.00 | -4.76% | 0.3M |
| 05-15 | $3.97 | $3.94 | -0.76% | 0.3M |
| 05-18 | $3.99 | $3.68 | -7.77% | 0.5M |
| 05-19 | $3.67 | $3.67 | +0.00% | 0.2M |
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.71M | $35.11M | $32.55M | $30.78M |
Operating Income | $-20.31M | $-86.88M | $-63.18M | $-35.67M |
Net Income | $-20.24M | $-79.20M | $-55.27M | $-25.74M |
EPS (Diluted) | $-0.16 | $-1.87 | $-2.87 | $-3.59 |
Total Assets | $270.28M | $290.46M | $163.56M | $105.17M |
Total Liabilities | $101.83M | $104.17M | $101.94M | $101.20M |
Cash & Equivalents | $216.91M | $217.05M | $69.63M | $39.22M |
Free Cash Flow OCF − CapEx | Not available | $-85.62M | $-70.09M | $-42.27M |
Shares Outstanding | 94.32M | 90.91M | 25.15M | 7.96M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.